Form 10-Q BIOGEN INC. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Biogen (BIIB) PT Lowered to $386 at Needham & Company
October 21, 2021 6:26 AM EDTNeedham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $386.00 (from $398.00) while maintaining a Buy rating.
The analyst commented, "While near term earnings remain strong, driven by the MS franchise, Aduhelm's uptake is essentially pushed out to after CMS's final... More
Biogen (BIIB) PT Lowered to $390 at Oppenheimer
October 20, 2021 6:05 PM EDTOppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $450.00) while maintaining an Outperform rating.
The analyst commented, "Bolstered by a 3Q top- and bottom-line beat, BIIB outlined a number of steps to support the Aduhelm launch but deferred... More
